Sandoz Group AG Shareholders Approve 2026 Resolutions

Sandoz Group AG, a leader in affordable medicines, announced that shareholders approved all proposals by its Board of Directors at the 2026 Annual General Meeting. This included the Annual Financial Statements and a CHF 0.80 dividend per registered share, equivalent to 27% of the core net income.

Gilbert Ghostine was re-elected as Chairman, with all other Board members confirmed for another year. 1,067 shareholders attended, representing 77.06% of registered shares. Ghostine addressed shareholders, expressing confidence in Sandoz's future prospects in healthcare.

Shareholders approved compensation packages for the Board and Executive Committee. KPMG AG was re-elected as the statutory auditor for 2026. Detailed resolutions are available on Sandoz's website.